Literature DB >> 25342084

Role of inflammation in diabetic macular edema.

Hidetaka Noma1, Tatsuya Mimura, Kanako Yasuda, Masahiko Shimura.   

Abstract

Vitreous fluid levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor (sVEGFR)-2, soluble intercellular adhesion molecule (sICAM)-1, monocyte chemotactic protein (MCP)-1 and pentraxin 3 (PTX3) were measured by enzyme-linked immunosorbent assay in 36 patients with diabetic macular edema (DME) and 15 patients with macular hole (MH). Aqueous flare values were measured with a laser flare meter, and macular edema was examined by optical coherence tomography. Vitreous fluid levels of VEGF, sVEGFR-2, sICAM-1, MCP-1 and PTX3 were significantly higher in the patients with DME than in those with MH. There was a significant correlation between the vitreous fluid level of sVEGFR-2 and the levels of sICAM-1, MCP-1 and PTX3. The aqueous flare value was significantly correlated with the vitreous fluid levels of sVEGFR-2, sICAM-1, MCP-1 and PTX3. These findings suggest that inflammatory factors may induce an increase in vascular permeability and disrupt the blood-aqueous barrier in DME patients. 2014 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25342084     DOI: 10.1159/000364955

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  23 in total

1.  A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.

Authors:  David G Callanan; Anat Loewenstein; Sunil S Patel; Pascale Massin; Borja Corcóstegui; Xiao-Yan Li; Jenny Jiao; Yehia Hashad; Scott M Whitcup
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-08       Impact factor: 3.117

Review 2.  Therapeutic Options in Refractory Diabetic Macular Oedema.

Authors:  Sanket U Shah; Raj K Maturi
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

Review 3.  Laser flare-cell photometer: principle and significance in clinical and basic ophthalmology.

Authors:  Mitsuru Sawa
Journal:  Jpn J Ophthalmol       Date:  2016-11-25       Impact factor: 2.447

4.  Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema.

Authors:  Masakazu Morioka; Yoshihiro Takamura; Yutaka Yamada; Takehiro Matsumura; Makoto Gozawa; Masaru Inatani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-09-20       Impact factor: 3.117

5.  Concentration of acute phase factors in vitreous fluid in diabetic macular edema.

Authors:  Kazuhiro Kimura; Tomoko Orita; Yuka Kobayashi; Shigeo Matsuyama; Kazushi Fujimoto; Kazuhiko Yamauchi
Journal:  Jpn J Ophthalmol       Date:  2017-07-28       Impact factor: 2.447

6.  Posterior subtenon infusion of triamcinolone acetonide as adjunctive treatment to panretinal photocoagulation using pattern scan laser for diabetic retinopathy.

Authors:  Yutaka Yamada; Yoshihiro Takamura; Takehiro Matsumura; Masakazu Morioka; Makoto Gozawa; Masaru Inatani
Journal:  Jpn J Ophthalmol       Date:  2018-10-17       Impact factor: 2.447

7.  Role of Combined Therapy of Intravitreal Ranibizumab and Dexamethasone in Refractory Diabetic Macular Edema: a Retrospective Study.

Authors:  Kaushik Sadhukhan; Subhrajyoti Naskar
Journal:  Maedica (Bucur)       Date:  2021-12

8.  Central Macular Thickness in Diabetic Macular Edema.

Authors:  H Gungel; H Aral; F Erdenen; M Gokce; S K Erdur
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Oct-Dec       Impact factor: 0.877

Review 9.  Diabetic Retinopathy: Vascular and Inflammatory Disease.

Authors:  F Semeraro; A Cancarini; R dell'Omo; S Rezzola; M R Romano; C Costagliola
Journal:  J Diabetes Res       Date:  2015-06-07       Impact factor: 4.011

10.  Ocular TGF-β, Matrix Metalloproteinases, and TIMP-1 Increase with the Development and Progression of Diabetic Retinopathy in Type 2 Diabetes Mellitus.

Authors:  Lucia Saucedo; Isabel B Pfister; Souska Zandi; Christin Gerhardt; Justus G Garweg
Journal:  Mediators Inflamm       Date:  2021-06-25       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.